These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25098457)

  • 21. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
    Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growing experience with mTOR inhibitors in pediatric solid organ transplantation.
    Ganschow R; Pape L; Sturm E; Bauer J; Melter M; Gerner P; Höcker B; Ahlenstiel T; Kemper M; Brinkert F; Sachse MM; Tönshoff B
    Pediatr Transplant; 2013 Nov; 17(7):694-706. PubMed ID: 24004351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for the management of adverse events associated with mTOR inhibitors.
    Kaplan B; Qazi Y; Wellen JR
    Transplant Rev (Orlando); 2014 Jul; 28(3):126-33. PubMed ID: 24685370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
    Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical application of mTORi based immunosuppression for renal transplantation in India.
    Chacko B
    Clin Transplant; 2012; 26(1):1-15. PubMed ID: 21906172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
    Barbari A; Maawad M; Kfoury Kassouf H; Kamel G
    Exp Clin Transplant; 2015 Oct; 13(5):377-86. PubMed ID: 26450460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
    Mulgaonkar S; Kaufman DB
    Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.